Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 40.15% is 32% above its 5-year average of 30.45%, near the high end of its 5-year range (7.34%–46.02%).
As of the fiscal period ended Tuesday, June 30, 2026. 61.11% above its 12-month average of 24.92%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 40.15%.
DEBT TO ASSETS RATIO
40.15%
DEBT TO ASSETS RATIO AVG TTM
24.92%
DEBT TO ASSETS RATIO AVG 3Y
32.14%
DEBT TO ASSETS RATIO AVG 5Y
30.45%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+61.11%
CURRENT VS 3Y AVG
+24.92%
CURRENT VS 5Y AVG
+31.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+44508.91%
vs the sector median at left
Treace Medical Concepts, Inc.
Market Cap
$259.49M
Debt to Assets Ratio
40.15%
TTM Avg
24.92%
3Y Avg
32.14%
5Y Avg
30.45%
Market Cap
$259.56M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.14M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.12M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.63M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.27M
Debt to Assets Ratio
0.31%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.43M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.92M
Debt to Assets Ratio
0.55%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Treace Medical Concepts, Inc. (TMCI) | $259.49M | 40.15% | 24.92% | 32.14% | 30.45% |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | 0.03% | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | 0.01% | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | 0.03% | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | 0.00% | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | 0.31% | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $256.47M | 0.03% | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | 0.55% | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 0.13% | N/A | N/A | N/A |
Debt/Assets
40.1%
Debt/Equity
1.07
Current Ratio
2.90
Interest Coverage
-10.2x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 40.15% |
| 2026-03-31 | 7.36% |
| 2025-12-31 | 7.34% |
| 2025-09-30 | 35.80% |
| 2025-06-30 | 33.95% |
| 2025-03-31 | 33.70% |
| 2024-12-31 | 32.08% |
| 2024-09-30 | 32.93% |
| 2024-06-30 | 30.90% |
| 2024-03-31 | 28.89% |
| 2023-12-31 | 27.91% |
| 2023-09-30 | 29.33% |
| 2023-06-30 | 27.89% |
| 2023-03-31 | 27.81% |
| 2022-12-31 | 43.13% |
| 2022-09-30 | 46.02% |
| 2022-06-30 | 44.58% |
| 2022-03-31 | 30.49% |
| 2021-12-31 | 20.85% |
| 2021-09-30 | 21.31% |
| 2021-06-30 | 20.57% |
| 2021-03-31 | 78.20% |
| 2020-12-31 | 74.10% |
